Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

App aims to keep stomach cancer patients fed through surgery

NCT ID NCT06385691

Symptom relief Sponsor: Centre Leon Berard Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a software tool called myDIET that helps manage nutrition in people with stomach or esophageal junction cancer who are scheduled for surgery. Patients answer simple questions about eating, weight, and symptoms, and the tool gives tailored advice. The goal is to see if using the tool helps patients start additional treatments sooner after surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
myDIET software tool
What this could lead to
If it works, this could provide a simple digital tool to help gastric cancer patients maintain better nutrition before and after surgery, potentially improving recovery and starting follow-up treatments sooner.
What could go wrong
This is a small, early-phase study with only 60 participants and no comparison group, so results may not apply widely. The tool relies on patient self-reporting, which can be inaccurate.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2024

Expected to finish

Oct 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient 18 years of age or older at date of signing informed consent to participate; * Histologically proven diagnosis of gastric adenocarcinoma or OGJ; * Localized, resectable disease; * Patients with an indication for perioperative chemotherapy and/or immunotherapy validated in multidisciplinary consultation meeting, with a scheduled surgery date at least 1 month after enrolment; * Performance status (ECOG): 0-2; * Membership of a social security scheme; * Signed informed consent to participate. Exclusion Criteria: * Other associated solid cancer or haemopathy; * Presence of severe comorbidity (Charlson index \> 9) * Presence of unbalanced dysthyroidism; * History of gastric, duodenal or esophageal surgery; * Inability to comply with study requirements, including : * Impossibility for the patient or his/her caregiver to connect to myDIET; * Difficulty in understanding the written French language; * Psychological incapacity (e.g. excessive vulnerability, psychiatric disorder) or physical incapacity (e.g. physical/motor disability); * Patient under guardianship, curatorship or safeguard of justice; * Patients already participating in a clinical trial or interventional study likely to interfere with the evaluation of the primary endpoint. * Pregnant or breast-feeding patient.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastric adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastric cancer gastric neoplasm gastroesophageal cancer gastroesophageal junction adenocarcinoma Motor Activity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gastric cancer Oesogastric junction cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre Léon Berard

    RECRUITING

    Lyon, 69008, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.